Digg StumbleUpon LinkedIn YouTube Flickr Facebook Twitter RSS Reset
Comments Off

GASTROINTESTINAL AND LIVER DISEASE – Exercise 35

By | Published: November 3, 2015

The multiple choice questions in this online test paper focuses on GASTROINTESTINAL AND LIVER DISEASE MCQ. If you are looking for self evaluation of your PG Medical entrance exam preparation then this online GASTROINTESTINAL AND LIVER DISEASE MCQ Test Paper will help you to evaluate your exam preparation.

Instruction for REPRODUCTIVE BIOLOGY/ REPRODUCTIVE MEDICINE / INFERTILITY MCQs:

1- This online MCQ practice test paper contains 30 questions.
2- Each question in this online practice test paper have four options and only 1 option is correct.
3- You can view the answers of this practice test paper after submitting the practice test paper.
Note: The answers mentioned at the end of practice test are the best suitable option as per our knowledge. Users shall cross-check the answers with their textbooks.

Q 1. following antiviral drugs has dual antiviral activity against HBV & HIV

 
 
 
 

Q 2. not a complication of chronic hepatitis B

 
 
 
 

Q 3. following side effects of IFN α therapy is irreversible on cessation of therapy

 
 
 
 

Q 4. for HBeAg negative chronic HBV infection antiviral therapy is indicated for patients with

 
 
 
 

Q 5. HBV inactive carriers is characterized by all except

 
 
 
 

Q 6. PEG stands for

 
 
 
 

Q 7. most important risk factor for development of cirrhosis & HCC in chronic HBV infection is

 
 
 
 

Q 8. first approved treatment of chronic HBV infection

 
 
 
 

Q 9. nephrotoxicity of adefovir is best related to

 
 
 
 

Q 10. which factor is the most important in progression of liver disease in chronic hepatitis C

 
 
 
 

Q 11. replicative phase of chronic HBV infection is characterized by

 
 
 
 

Q 12. antibody prevalent in patients with chronic HCV infection

 
 
 
 

Q 13. interferon α therapy is not effective in which of the following groups of CHB patients

 
 
 
 

Q 14. recommended regimen of peg IFNa-2a for CHB is

 
 
 
 

Q 15. most potent of the HBV antivirals is

 
 
 
 

Q 16. antibody seen in chronic hepatitis D

 
 
 
 

Q 17. for HBeAg reactive chronic HBV infection antiviral therapy is indicated for patients with

 
 
 
 

Q 18. patients with which HBV genotype has highest rate of IFN induced HBeAg loss

 
 
 
 

Q 19. most common symptom in chronic hepatitis C

 
 
 
 

Q 20. which of the following differentiates natural immunity by resolved HBV infection from that which is acquired through vaccination

 
 
 
 

Q 21. inhibitory dose of lamivudine for treating HBV/HIV coinfected patients is

 
 
 
 

Q 22. best prognostic indicator in chronic hepatitis C is

 
 
 
 

Q 23. serum HBV DNA undetectable by PCR is defined as

 
 
 
 

Q 24. in patients with HBV-HIV infection which should never be used as monotherapy

 
 
 
 

Q 25. extrahepatic complications unrelated to immune complex injury in chronic hepatitis C are all except

 
 
 
 

Q 26. following is approved for treatment of chronic HBV infection

 
 
 
 

Q 27. therapy with which of the following least likely to result in emergence of viral mutations

 
 
 
 

Q 28. nonreplicative phase of chronic HBV infection is characterized by all except

 
 
 
 

Q 29. in CHB, factor that is not predictive of a response to antiviral therapy is

 
 
 
 

Q 30. following drug is beneficial in severe acute hepatitis B

 
 
 
 


pgmedmin

Comments are closed.